The difference between lorlatinib and lorlatinib: two names for the same drug

Lorlatinib and lorlatinib, although they have different names, are actually the same anti-cancer drug, but they are transliterated differently in different contexts and cultural backgrounds. Its English generic name isLorlatinib, which is a well-known anti-cancer drug in the international market. When this drug enters different countries and regions, in order to better communicate with local medical professionals and patients, it will be translated and transliterated according to local language and phonetic rules. For example, in overseas markets, it may be sold under the trade name Lorbrena, while in the domestic market, we are more accustomed to calling it lorlatinib.

Lorlatinib is a drug designed to treat adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). As a third-generation ALK inhibitor, it can accurately inhibit the activity of ALK receptors, effectively block the growth and spread of tumor cells, and provide effective treatment for patients with non-small cell lung cancer. It is worth mentioning that this drug also has good blood-brain barrier penetration, which means that it can exert a therapeutic effect on tumor metastasis in the brain.

Clinically, lorlatinib has demonstrated significant therapeutic effects, not only prolonging patients’ survival but also significantly improving their quality of life. Lorlatinib provides new treatment options and hope for patients whose disease has progressed despite treatment with other ALK inhibitors. However, as with all powerful drugs, lorlatinib, while providing significant therapeutic benefits, may also come with some side effects. Therefore, patients must strictly follow their doctor's instructions when using this drug.